浙江丰茂科技股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Zhejiang Fengmao Technology Co., Ltd., has disclosed its 2025 semi-annual report, highlighting its operational performance and financial status, while ensuring compliance with relevant regulations and accurate information disclosure [10][18]. Company Basic Information - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6]. - The company does not have any preferred shareholders or related shareholding situations [7]. Financial Data and Indicators - The company raised a total of RMB 638 million through the issuance of 20 million shares at a price of RMB 31.90 per share, with a net amount of RMB 563.82 million after deducting issuance costs [18]. - As of June 30, 2025, the company has a remaining balance of RMB 227.04 million in its special account for raised funds, which includes RMB 71 million in structured deposits and RMB 60 million in financial products [28]. Fund Management and Usage - The company has established a management system for raised funds, ensuring compliance with laws and regulations, and has signed tripartite supervision agreements with banks and sponsors [21]. - The company has not used idle raised funds for temporary working capital or engaged in cash management during the reporting period [26]. - The company has approved the use of RMB 12.99 million of raised funds to replace self-raised funds for investment projects and RMB 9.37 million for issuance costs [24]. Changes in Fund Investment Projects - The company has made adjustments to the use of raised funds, reallocating funds from the "Tension Wheel Expansion Project" to the "Intelligent Chassis Thermal Control System Production Base (Phase I)" project due to the termination of the "Jiaxing Auto Parts Production Base Project" [30][31]. Disclosure of Fund Usage - The company has ensured that all disclosures regarding the usage of raised funds are timely, accurate, and complete, with no violations in fund management [31].